Untitled

Download a copy of this content.

HealthTrust presents…“Vaccine Current State & Addressing Hesitancy”

There are currently two messenger RNA (mRNA) vaccines available on Emergency Use Authorization (EUA) approval in the U.S. Two viral vector vaccines are likely to follow, with application for approval probable within the next few months. We are awaiting safety and efficacy data on the new vaccine candidates.  Questions remain regarding efficacy against the emerging COVID-19 strains, differences between vaccine platforms and delivery systems, and how best to address vaccine hesitancy—especially within minority populations. With additional EUA approvals on the horizon and greater availability of vaccines in the marketplace, HealthTrust has assembled an expert panel to answer these questions and more. Join us to access this important information.

Session Topics |  Attendees will learn how to…

1. Communicate how mRNA vaccines differ from Viral Vector vaccines and communicate safety and efficacy of all current and pending COVID-19 vaccines.
2. Recognize misinformation on vaccine safety and efficacy, including eligibility and contraindications to the COVID-19 vaccine.
3. Implement a plan to combat vaccine hesitancy.

Moderator:

John Young, M.D., MBA, FACHE  | Chief Medical Officer  |  HealthTrust

Panelists:

Jason Braithwaite, PharmD, MS, BCPS  |  Senior Director, Clinical Pharmacy Services  |  HealthTrust

Michelle D. Fiscus, M.D. FAAP  |  Medical Director | Vaccine-Preventable Diseases & Immunization Program  |  TennesseeDepartment of Health

Michael E. Nottidge, M.D., MPH, FACEP  |  Critical Care, TriStar Centennial Medical Center  |  HCA Healthcare

S. Shaefer Spires, M.D.  |  Assistant Professor of Medicine  |  Division of Infectious Diseases  |  Medical Director, DASON  |  Duke University School of Medicine

Target Audience: Hospital & Health System Leaders, Urgent Care & Clinical Setting Leaders, Assisted Living Facilities, Skilled Nursing Facilities, Pharmacists, Nurses & Physicians

Continuing Education:  No CE credit is available for this session.